Actively Recruiting
Comparing Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Led by Proton Collaborative Group · Updated on 2026-09-29
192
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to compare two treatment approaches for men with intermediate risk localized prostate cancer. The study evaluates proton beam radiation therapy alone versus proton therapy combined with androgen suppression therapy. The goal is to better understand the benefits and potential side effects of adding androgen suppression to radiation treatment. Participants receive one of two treatments either hypofractionated proton radiation therapy alone, given in 28 treatments over about 5.5 to 6.5 weeks, or proton therapy combined with androgen suppression therapy started 8 to 10 weeks before radiation and continued for about six months. Radiation options also include high dose IMRT alone or a combination of brachytherapy and IMRT, depending on the treatment arm. During the study, participants will be monitored regularly for side effects and treatment outcomes. Researchers will assess morbidity outcomes after at least three years of follow-up, along with toxicity levels, quality of life, biochemical failure rates, clinical failure, survival, and hormone levels over a five-year period. The study involves multiple assessments to gather data on the effects of the treatments on prostate cancer and patient well-being.
CONDITIONS
Brief Title
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here